trending Market Intelligence /marketintelligence/en/news-insights/trending/dlnivy3bvkdytjqvvvk7pg2 content esgSubNav
In This List

US court dismisses suit against Biogen related to blockbuster drug Tecfidera

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


US court dismisses suit against Biogen related to blockbuster drug Tecfidera

Biogen Inc. is no longer facing a lawsuit that alleged it misled shareholders on the financial performance and safety of its blockbuster drug Tecfidera, Reuters reported.

U.S. District Judge Dennis Saylor tossed the lawsuit out on grounds that plaintiffs failed to establish the company's executives made false or misleading statements intentionally or recklessly.

The Cambridge, Mass.-based biotechnology company's Tecfidera — a treatment for multiple sclerosis — generated $4.2 billion in sales in 2017.